BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis

@article{Pochon2010BR55AL,
  title={BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis},
  author={S. Pochon and I. Tardy and P. Bussat and T. Bettinger and J. Brochot and M. V. von Wronski and L. Passantino and M. Schneider},
  journal={Investigative Radiology},
  year={2010},
  volume={45},
  pages={89-95}
}
  • S. Pochon, I. Tardy, +5 authors M. Schneider
  • Published 2010
  • Chemistry, Medicine
  • Investigative Radiology
  • Objectives:BR55, an ultrasound contrast agent functionalized with a heterodimer peptide targeting the vascular endothelial growth factor receptor 2 (VEGFR2), was evaluated in vitro and in vivo, demonstrating its potential for specific tumor detection. Materials and Methods:The targeted contrast agent was prepared by incorporation of a biospecific lipopeptide into the microbubble membrane. Experiments were performed in vitro to demonstrate the binding capacities of BR55 microbubbles on… CONTINUE READING
    228 Citations
    A Lipopeptide-Based αvβ₃ Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis.
    • 22
    Ultrasound Molecular Imaging of VEGFR2 in a Rat Prostate Tumor Model Using BR55
    • 112
    VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    • 17
    • PDF

    References

    SHOWING 1-10 OF 33 REFERENCES
    Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
    • 178
    Targeting vascular endothelium with avidin microbubbles.
    • 91
    In vivo ultrasound imaging of thrombi using a target-specific contrast agent.
    • 21